Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 1

Conditions

Lymphoma 260Lymphoma, Non-Hodgkin 205Leukemia, Lymphocytic, Chronic, B-Cell 193Lymphoma, Large B-Cell, Diffuse 187Lymphoma, Follicular 168Lymphoma, Mantle-Cell 134Leukemia 81Lymphoma, B-Cell, Marginal Zone 80Burkitt Lymphoma 54Waldenstrom Macroglobulinemia 52Precursor Cell Lymphoblastic Leukemia-Lymphoma 48Lymphoma, B-Cell 47Lymphoma, Large-Cell, Immunoblastic 42Hodgkin Disease 39Recurrence 35Lymphoma, Large-Cell, Anaplastic 18Multiple Myeloma 16Neoplasms 13Myelodysplastic Syndromes 12Hematologic Neoplasms 12Leukemia, Myeloid, Acute 11Lymphoma, T-Cell 9Intraocular Lymphoma 9Dendritic Cell Sarcoma, Interdigitating 9Leukemia, Prolymphocytic 7Neoplasms, Plasma Cell 6Leukemia, Hairy Cell 6Leukemia, B-Cell 6Graft vs Host Disease 6Arthritis, Rheumatoid 6

Interventions

Rituximab 2dexamethasone acetate 1Dexamethasone 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Opsoclonus-Myoclonus Syndrome × Rituximab × Clear all
NCT01868269 2025-02-03

Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)

Institut Curie

Phase 3 Completed
102 enrolled
CNS

Neuroblastoma, Opsoclonus-Myoclonus Syndrome

NCT00244361 2011-05-10

Effectiveness of Rituximab in Pediatric OMS Patients.

National Pediatric Neuroinflammation Organization, Inc.

Phase 1/2 Completed
25 enrolled

Ataxia, Myoclonus, Ocular Motility Disorders, Opsoclonus-Myoclonus Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡